You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Among other projects, PacBio is working with LabCorp to sequence a large number of SARS-CoV-2 genomes from de-identified positive samples.
The data identified common variants that alter gene expression constantly across development, or predominantly during the prenatal or postnatal stages.
Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.
In Science this week: sequencing of diverse human genomes gives insight into genetic variation and population history, commentary on data sharing, and more.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
The New York Times reports on how an international team of researchers is working to find drugs that may affect how SARS-CoV-2 interacts with host proteins.
The partners' "COVID-19 task force" will invest in ePlex molecular testing platforms from GenMark Diagnostics to quadruple UCSF's testing capacity.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PLOS this week: sub-telomeric sequence diversity in dozens of human populations, variant linked to ataxia in dog breed, and more.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.